Physician profile
James Hart
NPI 1871783522
$2,663.99
in general payments reported to CMS, 2019-2025
22 companies · $130 in 2025
The $130 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,031 · 2020: $464 · 2021: $264 · 2022: $17.79 · 2023: $319 · 2024: $439 · 2025: $130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $888.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $887.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $641.15 | 2019-2025 | Spravato, Invega Sustenna |
| Teva Pharmaceuticals USA, INC. | $319.51 | 2019-2024 | Uzedy |
| Sunovion Pharmaceuticals INC. | $290.85 | 2019-2020 | |
| Allergan, INC. | $224.87 | 2019-2020 | |
| Alkermes, INC. | $206.93 | 2023-2025 | Lybalvi, Aristada |
| Otsuka America Pharmaceutical, INC. | $174.37 | 2019-2024 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $158.24 | 2019-2021 | |
| Neuronetics, INC. | $119.08 | 2019 | |
| Abbvie INC. | $112.24 | 2021-2023 | |
| Neurocrine Biosciences, INC. | $104.06 | 2020-2025 | Ingrezza |
| Idorsia Pharmaceuticals US INC | $63.11 | 2023 | Quviviq |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $42.58 | 2024-2025 | Caplyta |
| Adlon Therapeutics L.P. | $32.62 | 2021 | |
| Shire North American Group INC | $29.69 | 2019 | |
| Avanir Pharmaceuticals, INC. | $24.34 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $21.26 | 2023 | Perseris |
| Jazz Pharmaceuticals INC. | $20.65 | 2021 | |
| Eisai INC. | $18.57 | 2020 | |
| Vanda Pharmaceuticals INC. | $17.32 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.44 | 2019 | |
| Almatica Pharma LLC | $13.84 | 2023 | Loreev Xr |
| Acadia Pharmaceuticals INC | $12.27 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Hart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.